Highest-materiality recent filing
LivaNova Q1 revenue $362.3M (+14.3% YoY); raises FY2026 guidance; FDA PMA for aura6000 OSA system
Q1 revenue $362.3M (+14.3% reported, +11.1% CC); GAAP EPS $0.40, adjusted EPS $0.98.
LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%
Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.
LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90
Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.
LivaNova Q2 revenue $352.5M (+10.7%), raises FY25 adjusted EPS guidance to $3.70-$3.80
Revenue $352.5M, +10.7% reported, +10.3% organic; GAAP EPS $0.50, adjusted EPS $1.05.
Italian Ministry seeks €108.8M minimum costs in SNIA case; LivaNova disputes
On May 15, 2025, Italian Ministry served filing to Court of Appeal seeking minimum costs of approximately €108.8M, contrary to Supreme Court's decision that disapproved €157.3M.
Revenue $316.9M, +7.4% reported, +10.4% organic vs Q1 2024.
LivaNova to record ~€333M liability after Italian Supreme Court ruling on SNIA environmental case
Italian Supreme Court rules LivaNova jointly liable for SNIA environmental liabilities of €454M, but excludes €157M in prior payments.
LivaNova Q4 revenue $321.8M (+6.8% organic); FY2025 adjusted EPS guidance $3.65-$3.75
Q4 revenue $321.8M (+6.8% organic YoY); GAAP EPS $1.02, adjusted EPS $0.81.
LivaNova Q3 revenue $318.1M (+11.2% YoY); raises FY2024 guidance
Revenue of $318.1M, up 11.2% reported and constant-currency; ex-ACS wind down, growth 12.3% constant-currency.
LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook
Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.
LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive
Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.
LivaNova issues $345M convertible notes, repurchases $230M of existing debt
Issued $345M aggregate principal of 2.50% convertible senior notes due 2029
Priced $300M aggregate principal of 2.50% convertible senior notes due 2029; initial purchasers may buy up to $45M more.
LivaNova announces $300M convertible note offering due 2029, with $45M greenshoe
Proposed $300M convertible senior notes due 2029; initial purchasers granted 13-day option for additional $45M.
LivaNova Q4 revenue $310M (+12.8%), adj. EPS $0.87; full-year $1.15B; new CEO
Q4 revenue $310.1M, up 12.8% reported (11.9% constant currency) vs prior year.
LivaNova appoints Vladimir Makatsaria as CEO effective March 1, 2024; Kozy remains Chair
Vladimir Makatsaria, former J&J MedTech Ethicon head, named CEO and Board member effective March 1, 2024.
On October 8, 2024, the Board of Directors (the “Board”) of LivaNova PLC (the “Company”) appointed Susan Podlogar to the Board and as a member of the Compensation and Human Capital Management Committee of the Board.
On September 10, 2024, LivaNova PLC (the “Company”) announced that Trui Hebbelinck, the Company’s Chief Human Resources Officer, will leave her position on September 30, 2024 and commence a period of garden leave.
William A. Kozy will step down from his current position as Interim Chief Executive Officer of the Company on March 1, 2024 but will remain the Chair of the Board.
In addition, Mr. Makatsaria was appointed as a member of the Board as of the Effective Date.
the Company’s Board of Directors (the “Board”) appointed Vladimir A. Makatsaria as Chief Executive Officer of the Company, effective as of March 1, 2024
Max materiality 0.90 · Median 0.75 · Most common event earnings